Faculty

Hemant Vaidya
Lecturer - Spring 2014

Hemant Vaidya, Ph.D., is currently an independent consultant in the In-Vitro Diagnostics (IVD) space and a professor at the UCD Graduate School of Management.  He has worked in the IVD Industry for 24 years in various capacities. He started out as a bench scientist developing Immunoassays for cardiac and thyroid markers and grew in the ranks to become the Director of Clinical and Scientific affairs for Chemistry/ Immunochemistry diagnostics business and then the Vice-President of R&D for the Molecular and Microbiology diagnostics business. He was part of the team at Washington University that developed the first monoclonal antibody for creatine kinase MB, a biochemical marker for myocardial infarction (heart attack), which was patented and widely licensed in the industry.

In his last role as VP of R&D for 14 years, he was responsible for planning all aspects of product development from concept to commercialization, including annual operating plan and short and long term strategy and technology road map. Throughout his career in industry and as leader of the R&D organization, he promoted innovation and intrapreurship to create new product concepts to grow the business. He was a key player in identifying customer needs to create new opportunities in the emerging markets. He constantly challenged the status quo and looked for ways to improve the product development process to gain efficiency. During his tenure the microbiology business grew from a $140MM to $210MM. In this leadership role his interaction with other functions such as marketing, regulatory, manufacturing, sales, service etc. gave him appreciation and an in-depth understanding of the business processes and product life cycle management.

He has provided mentorship to several entrepreneurs in US and recently joined the Sacramento Angels. He also mentors several entrepreneurs in India through a mentoring program of Indian Institute of Management, Ahmedabad.

He has a Ph.D. degree in Microbiology and post doctoral training in Clinical Chemistry. He has authored four patents and twenty five publications.

Commands

Twitter Feed

Loading tweets...

Spotlight Story

Andrew Barkett Finds Innovative Ways to Fuel Entrepreneurship
Named First-ever Chief Technology Officer for Republican National Committee

Image of Andrew Barkett Finds Innovative Ways to Fuel Entrepreneurship

UPDATE: Andrew Barkett is leaving his post as senior engineer at Facebook to bring his decade of experience in Silicon Valley to become the first-ever chief technology officer for the Republican National Committee.The June 4 announcement has stirred a whirlwind of media coverage, including the Huffington Post and Washington Post.Bark

Spotlight Story

MBA Student Consultants Make an IMPACT
Projects Put Business Needs Front and Center

Image of MBA Student Consultants Make an IMPACT

Agilent Technologies’ Electronic Measurement Group is a $3.6 billion business that over the past decade has seen a dramatic shift in its customer base from U.S., and Western European customers to predominantly Asia-based customers. Today, the majority of the division’s revenues are generated outside of the U.S., with an increasing concentration in China.

Spotlight Story

UC Davis Part-Time MBA in Top 8%, Full-Time MBA in Top 9%
U.S. News & World Report’s latest rankings: This marks the 19th consecutive year our MBA program has been ranked among the best in the nation.

Image of  UC Davis Part-Time MBA in Top 8%, Full-Time MBA in Top 9%

(Davis, CA) — The UC Davis Graduate School of Management’s full-time MBA program has been ranked among the top six percent of AACSB International-accredited programs nationwide, according to U.S. News & World Report’s latest graduate business school rankings released today.

Spotlight Story

Mark Otero MBA 07 Builds Sacramento’s Coolest Company
The secret of social gaming mogul Mark Otero’s success is taking things to the extreme

Image of Mark Otero MBA 07 Builds Sacramento’s Coolest Company

The secret of Midtown Sacramento’s Facebook gaming mogul Mark Otero’s success is taking things to the extreme.